Exercise of Options and Total Voting Rights

Tissue Regenix Group PLC

31 August 2023

 

Tissue Regenix Group plc

('Tissue Regenix', the 'Company' or the 'Group')

Exercise of Options

And Total Voting Rights

Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces that it has received notification for the exercise of options to subscribe for 216,519 new ordinary shares in the Company ("Ordinary Shares") at an exercise price of 27.6 pence per Ordinary Share. These shares are being issued pursuant to an exercise of options under the 2020 Tissue Regenix Group plc SAYE Option Plan. 

The above number includes 65,217 Ordinary Shares issued to Kirsten Lund, a PDMR of the Company. Following the issue, Kirsten will hold 65,217 Ordinary Shares, representing 0.09% of the Company's issued share capital.

The 216,519  new Ordinary Shares will rank pari passu with the existing Ordinary Shares and application has been made for these new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will occur at 8:00 a.m. on 6 September 2023.

Total Voting Rights

Following the issue of the 216,519 new Ordinary Shares, the Company will have a total of 70,574,468 Ordinary Shares in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For more information:

Tissue Regenix Group plc		www.tissueregenix.com
Daniel Lee, Chief Executive Officer		Via Walbrook PR
finnCap Ltd (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR & IR)	Tel: [phone]
Alice Woodings/Lianne Applegarth	[e-mail]

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in the field of regenerative medicine. The Company's patented decellularisation technology ('dCELL®') removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle and wound care.

In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech company that specialises in regenerative medicine and is dedicated to the development of high-quality, innovative tissue scaffolds, which can enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

 

END